User:Mr. Ibrahem/Iloperidone
From Wikipedia, the free encyclopedia
Iloperidone, sold under the brand name Fanapt and Zomaril, is an atypical antipsychotic used to treat schizophrenia.[1] It is taken by mouth.[1] Effects can take two to three weeks to occur.[2]
Clinical data | |
---|---|
Trade names | Fanapt, Zomaril |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609026 |
License data |
|
Routes of administration | By mouth |
Drug class | Atypical antipsychotic[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 96% (by mouth; Tmax = 2–4 hours) |
Protein binding | ~97% |
Metabolism | Liver (CYP2D6-mediated hydroxylation and CYP3A4-mediated O-demethylation) |
Onset of action | 2 to 3 wks[2] |
Elimination half-life | 18–33 hours |
Excretion | urine (45.1–58.2%) and feces (19.9–22.1%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C24H27FN2O4 |
Molar mass | 426.488 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Common side effects include sleepiness, dizziness, dry mouth, low blood pressure with standing, and weight gain.[1] Other side effects may include increased risk of death in older people with dementia, priapism, QT prolongation, neuroleptic malignant syndrome, tardive dyskinesia, milk production, and diabetes.[1] It is believed to work by affecting dopamine and 5-hydroxytryptamine.[2]
Iloperidone was approved for medical use in the United States in 2009.[1] Approval was refused in Europe in 2017 due to modest benefit and concerns of side effects.[2] In the United States, at a dose of 6 mg twice per day, a month of treatment costs about 2,100 USD as of 2021.[3]